Dupont Merck
As of the edition of 20 October 2026, Dupont Merck runs 11 drugs, 11 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Naltrexone | none listed | 6 |
| Warfarin | none listed | 1 |
| Amantadine | none listed | 0 |
| Nalbuphine | none listed | 1 |
| Nicardipine | none listed | 4 |
| Oxymorphone | Ends 2029 (patent) | 0 |
| Technetium sestamibi | none listed | 0 |
| Molindone | none listed | 0 |
| Anisotropine | none listed | 0 |
| Bretylium | none listed | 0 |
| Technetium bicisate | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Immune system: 4 trials led
- Infections: 4 trials led
- Urinary and reproductive: 4 trials led